Assessment of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of APB-R3
Status:
Not yet recruiting
Trial end date:
2023-11-03
Target enrollment:
Participant gender:
Summary
This will be a single centre, Phase 1, First-In-Human, Randomized, Double-Blind,
Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and
Pharmacodynamics of Single Ascending Dose of APB-R3 in Healthy Participants.